Amanda K. Lukens

Amanda K. Lukens

Auto-generated profile, based on publicly available information

Amanda K. Lukens

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2018 in Science
Verified
Journal Article
Open access
PDF file
ACAnnie N. Cowell
Annie N. Cowell
EIEva S. Istvan
Eva S. Istvan
ALAmanda K. Lukens
Amanda K. Lukens
MGMaria G. Gomez-Lorenzo
Maria G. Gomez-Lorenzo
MVManu Vanaerschot
Manu Vanaerschot
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
Dissecting Plasmodium drug resistance: Malaria is a deadly disease with no effective vaccine. Physicians thus depend on antimalarial drugs to save lives, but such compounds are often rendered ineffective when parasites evolve resistance. Cowell et al. systematically studied patterns of Plasmodium falciparum genome evolution by analyzing the sequences of clones that were resistant to diverse antimalarial compounds across the P. falciparum life cycle (see the Perspective by Carlton). The findings identify hitherto unrecognized drug targets and drug-resistance genes, as well as additional alleles in known drug-resistance genes. Science , this issue p. 191 ; see also p. 159

7 December 2018 in Science
Verified
Journal Article
Open access
PDF file
YAYevgeniya Antonova-Koch
Yevgeniya Antonova-Koch
SMStephan Meister
Stephan Meister
MAMatthew Abraham
Matthew Abraham
MLMadeline R. Luth
Madeline R. Luth
SOSabine Ottilie
Sabine Ottilie
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
A path to tackle liver-stage parasites: Malaria parasites are evolutionarily prepared to resist drug attack. Resistance is emerging to even the latest frontline combination therapies, which target the blood stages of the Plasmodium parasite. As an alternative strategy, Antonova-Koch et al. investigated the possibilities of drugs against liver-stage parasites (see the Perspective by Phillips and Goldberg). To do so, they devised a luciferase-reporter drug screen for the rodent parasite Plasmodium berghei. Three rounds of increasingly stringent screening were used. From this regime, several chemotypes that inhibit Plasmodium mitochondrial electron transport were identified. Excitingly, several new scaffolds, with as-yet-unknown modes of action but solely targeting the parasites' liver stages, emerged as promising drug leads for further development. Science , this issue p. eaat9446 ; see also p. 1112

1 April 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JDJohanna P. Daily
Johanna P. Daily
KRKarine G. Le Roch
Karine G. Le Roch
OSOusmane Sarr
Ousmane Sarr
DNDaouda Ndiaye
Daouda Ndiaye
ALAmanda Lukens
Amanda Lukens
DWDyann F. Wirth
Dyann F. Wirth
Infections with the human parasite Plasmodium falciparum continue to present a great challenge to global health. Fundamental questions regarding the

15 September 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
BFBarbara Forte
Barbara Forte
SOSabine Ottilie
Sabine Ottilie
APAndrew Plater
Andrew Plater
BCBrice Campo
Brice Campo
KDKoen J. Dechering
Koen J. Dechering
IGIan H. Gilbert
Ian H. Gilbert
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MalDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.

1 February 2022 in Cell Chemical Biology
Verified
Journal Article
Open access
RSRobert L. Summers
Robert L. Summers
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
JPJoao P. Pisco
Joao P. Pisco
JSJosefine Striepen
Josefine Striepen
MLMadeline R. Luth
Madeline R. Luth
ALAmanda K. Lukens
Amanda K. Lukens
We identify the Plasmodium falciparum acetyl-coenzyme A synthetase (PfAcAS) as a druggable target, using genetic and chemical validation. In vitro evolution of resistance with two antiplasmodial drug-like compounds (MMV019721 and MMV084978) selects for mutations in PfAcAS. Metabolic profiling of compound-treated parasites reveals changes in acetyl-CoA levels for both compounds. Genome editing confirms that mutations in PfAcAS are sufficient to confer resistance. Knockdown studies demonstrate that PfAcAS is essential for asexual growth, and partial knockdown induces hypersensitivity to both compounds. In vitro biochemical assays using recombinantly expressed PfAcAS validates that MMV019721 and MMV084978 directly inhibit the enzyme by preventing CoA and acetate binding, respectively. Immunolocalization studies reveal that PfAcAS is primarily localized to the nucleus. Functional studies demonstrate inhibition of histone acetylation in compound-treated wild-type, but not in resistant parasites. Our findings identify and validate PfAcAS as an essential, druggable target involved in the epigenetic regulation of gene expression.

4 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RMRebecca E. K. Mandt
Rebecca E. K. Mandt
MLMaria Jose Lafuente-Monasterio
Maria Jose Lafuente-Monasterio
TSTomoyo Sakata-Kato
Tomoyo Sakata-Kato
MLMadeline R. Luth
Madeline R. Luth
DSDelfina Segura
Delfina Segura
DWDyann F. Wirth
Dyann F. Wirth
The malaria parasite Plasmodium falciparum readily develops resistance to dihydroorotate dehydrogenase inhibitors in vitro and in a mouse model of infection.